Longevity Vision Fund
Longevity Vision Fund invests in technologies that have the potential to disrupt life sciences and extend healthy lifespan.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Longevity Vision Fund Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Longevity Vision Fund is a $100M investment fund dedicated to making longevity affordable and accessible to all. The fund accelerates longevity breakthroughs by investing in companies that develop technologies, products, and services that extend healthy human lifespans and overcome the negative effects of aging Longevity Vision Fund provides Seed to Series C funding to biotech and life extension-focused companies that have demonstrated affordable longevity potential and vision of milestones driving up the value of the company and market validation.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2021 | Exo | Series C | 0 |
| 9/2019 | Insilico Medicine | Series B | 37M |
| 8/2019 | Exo | Series B | 0 |
| 6/2021 | Senda Biosciences | Series B | 0 |
| 11/2020 | Eko | Series C | 0 |
| 4/2022 | Tessera Therapeutics | Series C | 0 |
| 1/2021 | Tessera Therapeutics | Series B | 0 |
| 7/2019 | Freenome | Series B | 160M |
| 8/2022 | Senda Biosciences | Series C | 123M |
| 10/2019 | LyGenesis | Debt Financing | 4M |
| 8/2019 | Juvenescence | Series B | 0 |
| 7/2019 | Valo Health | Series A | 100M |
| 3/2020 | Sigilon | Series B | 80.3M |
| 12/2020 | LyGenesis | Convertible Note | 11M |
| 8/2021 | Laronde | Series B | 440M |
| 9/2019 | Insilico Medicine | Series B | 37M |
| 6/2020 | 4D Molecular Therapeutics | Series C | 0 |
| 11/2021 | Biolinq | Series B | 0 |
| 1/2021 | Valo Health | Series B | 190M |
| 7/2020 | Deep Longevity | Series A | - |
| 4/2022 | Tessera Therapeutics | Series C | 0 |
| 11/2021 | Biolinq | Series B | 0 |
| 8/2021 | Laronde | Series B | 0 |
| 7/2021 | Exo | Series C | 0 |
| 6/2021 | Senda Biosciences | Series B | 0 |
| 1/2021 | Tessera Therapeutics | Series B | 0 |
| 1/2021 | Valo Health | Series B | 0 |
| 12/2020 | LyGenesis | Convertible Note | 0 |
| 11/2020 | Eko | Series C | 0 |
| 7/2020 | Deep Longevity | Series A | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
